A new study presented at the Annual Scientific Meetings of the Canadian Society of Pharmacology and Therapeutics found that Xarelto (generic name rivaroxaban) is transferred rapidly through the placenta, both from mother to fetus and fetus to mother. The study is the first to show evidence that Xarelto diffuses through the placenta and may be unsafe for pregnant women.
The blood thinner is used to prevent blood clots and stroke, especially in patients who have undergone surgery or experienced previous clotting issues. However, hundreds of Xarelto complaints submitted to the U.S. Food and Drug Administration suggest the anticoagulant carries risks of severe side effects.
The FDA has ordered more research after many patients have suffered additional strokes and blood clots while taking Xarelto. The drug, which does not have a natural antidote, could lead to an increased risk of irreversible internal hemorrhaging.